We are live on ! Find out more
ELDN icon

Eledon Pharmaceuticals
ELDN

49 hedge funds and large institutions have $32.1M invested in Eledon Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 12 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 12

8% less funds holding

Funds holding: 53 → 49 (-4)

30% less capital invested

Capital invested by funds: $46M → $32.1M (-$13.9M)

36% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 11

Holders
49
Holders Change
-4
Holders Change %
-7.55%
% of All Funds
1.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
18
Reduced
12
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$4.92M
2
SAM
Senzar Asset Management
New York
+$3.86M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$388K
4
BCM
Bridgeway Capital Management
Texas
+$302K
5
Bank of America
Bank of America
North Carolina
+$187K

Top Sellers

Rank Fund Capital Flow
1
Bank of New York Mellon
Bank of New York Mellon
New York
-$3.46M
2
GOCM
Green Owl Capital Management
New York
-$1.16M
3
Ameriprise
Ameriprise
Minnesota
-$989K
4
KCM
Kingdon Capital Management
New York
-$767K
5
OPPM
Opus Point Partners Management
New York
-$541K
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$101K – – –
ProShare Advisors
27
ProShare Advisors
Maryland
$100K -$10.8K -11 -9%
Renaissance Technologies
28
Renaissance Technologies
New York
$96K -$151K -154 -59%
Citigroup
29
Citigroup
New York
$92K +$22.6K +23 +29%
Millennium Management
30
Millennium Management
New York
$82K -$160K -163 -64%
TA
31
Teachers Advisors
New York
$78K – – –
RhumbLine Advisers
32
RhumbLine Advisers
Massachusetts
$64K +$2.94K +3 +4%
DekaBank Deutsche Girozentrale
33
DekaBank Deutsche Girozentrale
Germany
$56K +$63.8K +65 New
New York State Common Retirement Fund
34
New York State Common Retirement Fund
New York
$48K – – –
FMA
35
FNY Managed Accounts
New York
$36.1K +$39.3K +40 New
BA
36
BlackRock Advisors
Delaware
$35K +$11.8K +12 +46%
NFA
37
Nationwide Fund Advisors
Ohio
$34K – – –
RWA
38
Ropes Wealth Advisors
Massachusetts
$34K – – –
AIG
39
American International Group
New York
$31K – – –
Creative Planning
40
Creative Planning
Kansas
$19K – – –
BJ
41
BlackRock Japan
Japan
$10K +$4.91K +5 +83%
Manulife (Manufacturers Life Insurance)
42
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$10K +$9.82K +10 +1,000%
Morgan Stanley
43
Morgan Stanley
New York
$5K -$24.5K -25 -81%
BlackRock
44
BlackRock
New York
$2K +$982 +1 +100%
MFS
45
MSI Financial Services
Massachusetts
$2K +$1.96K +2 New
Barclays
46
Barclays
United Kingdom
$1K -$1.96K -2 -67%
Bank of Montreal
47
Bank of Montreal
Ontario, Canada
$1K +$1.96K +2 New
Wells Fargo
48
Wells Fargo
California
$1K +$1.96K +2 New
Geode Capital Management
49
Geode Capital Management
Massachusetts
$294 -$982 -1 -0.3%
GOCM
50
Green Owl Capital Management
New York
– -$1.16M -818 Closed
1
2
3

ELDN Hedge Fund Activity: Q1 2016 in Review

49 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q1 2016, worth a combined $32.1M — down 30% from $46M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ELDN and 7 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 18 added.

The largest buyer was Sabby Management, opening a new position worth an estimated $4.92M. The largest seller was Bank of New York Mellon, cutting an estimated $3.46M.

  • 49 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q1 2016, down from 53 in Q4 2015.
  • Funds reported $32.1M of Eledon Pharmaceuticals stock for Q1 2016, down 30% quarter-over-quarter.
  • 7 funds opened new Eledon Pharmaceuticals positions in Q1 2016 and 11 closed out, a net change of -4 holders.
  • The largest Eledon Pharmaceuticals buyer in Q1 2016 was Sabby Management, an estimated $4.92M added.
  • The largest Eledon Pharmaceuticals seller in Q1 2016 was Bank of New York Mellon, an estimated $3.46M sold.

Based on aggregated 13F filings for Q1 2016.